Sign in or create an account to add this stock to your watchlist.
About Seres Therapeutics (NASDAQ:MCRB)
Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing biological drugs designed to restore health by repairing the function of a dysbiotic microbiome. Its lead product candidate is SER-109, a bacterial spore ecology, which is in Phase III clinical study to treat multiply recurrent Clostridium difficile infection (CDI). The company is also developing SER-287 that is in Phase Ib clinical study in patients with mild-to-moderate ulcerative colitis; and SER-262, a multi-strain Ecobiotic microbiome therapeutic candidate, which is in Phase Ib study in patients with primary CDI. In addition, its product candidates in pre-clinical development comprise SER-301, an Ecobiotic microbiome therapeutic candidate for the treatment of inflammatory bowel disease; SER-401 for use with checkpoint inhibitors in patients with solid tumors; and SER-155, an Ecobiotic microbiome therapeutic candidate for the prevention of transplant-related mortality. Seres Therapeutics, Inc. has a strategic collaboration with Nestle Health Science and Memorial Sloan Kettering Cancer Center. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:MCRB
CUSIPN/A
Phone617-945-9626
Debt
Debt-to-Equity Ratio0.85
Current Ratio3.60
Quick Ratio3.60
Price-To-Earnings
Trailing P/E Ratio-3.78
Forward P/E Ratio-3.30
P/E GrowthN/A
Sales & Book Value
Annual Sales$32.10 million
Price / Sales10.57
Cash FlowN/A
Price / CashN/A
Book Value$0.25 per share
Price / Book33.40
Profitability
EPS (Most Recent Fiscal Year)($2.21)
Net Income$-89,380,000.00
Net Margins-277.79%
Return on Equity-150.44%
Return on Assets-47.26%
Miscellaneous
Employees138
Outstanding Shares40,650,000
Seres Therapeutics (NASDAQ:MCRB) Frequently Asked Questions
What is Seres Therapeutics' stock symbol?
Seres Therapeutics trades on the NASDAQ under the ticker symbol "MCRB."
How were Seres Therapeutics' earnings last quarter?
Seres Therapeutics (NASDAQ:MCRB) posted its quarterly earnings data on Wednesday, May, 9th. The biotechnology company reported ($0.69) EPS for the quarter, beating the Zacks' consensus estimate of ($0.75) by $0.06. The biotechnology company had revenue of $3.97 million for the quarter, compared to the consensus estimate of $3 million. Seres Therapeutics had a negative net margin of 277.79% and a negative return on equity of 150.44%. View Seres Therapeutics' Earnings History.
When is Seres Therapeutics' next earnings date?
What price target have analysts set for MCRB?
8 equities research analysts have issued 12-month price objectives for Seres Therapeutics' stock. Their predictions range from $19.00 to $20.00. On average, they anticipate Seres Therapeutics' share price to reach $19.3333 in the next year. View Analyst Ratings for Seres Therapeutics.
Who are some of Seres Therapeutics' key competitors?
Some companies that are related to Seres Therapeutics include Impax Laboratories (IPXL), Amneal Pharmaceuticals (AMRX), Biohaven Pharmaceutical (BHVN), Radius Health (RDUS), WAVE Life Sciences (WVE), Theravance Biopharma (TBPH), Mirati Therapeutics (MRTX), Epizyme (EPZM), Uniqure (QURE), Zai Lab (ZLAB), Intra-Cellular Therapies (ITCI), Immuron (IMRN), Retrophin (RTRX), Revance Therapeutics (RVNC) and Apellis Pharmaceuticals (APLS).
Who are Seres Therapeutics' key executives?
Seres Therapeutics' management team includes the folowing people:
- Dr. Roger James Pomerantz, Chairman, Pres & CEO (Age 61)
- Dr. Noubar B. Afeyan Ph.D., Co-Founder & Lead Independent Director (Age 55)
- Mr. Thomas J. DesRosier, Chief Legal Officer, Exec. VP & Sec. (Age 63)
- Mr. Eric D. Shaff, COO, CFO, Exec. VP & Principal Accounting Officer (Age 42)
- Dr. John G. Aunins, CTO and Exec. VP of Bioprocess & Manufacturing (Age 57)
When did Seres Therapeutics IPO?
(MCRB) raised $101 million in an IPO on Friday, June 26th 2015. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and BofA Merrill Lynch served as the underwriters for the IPO and Leerink Partners and Canaccord Genuity were co-managers.
Has Seres Therapeutics been receiving favorable news coverage?
Media coverage about MCRB stock has been trending somewhat positive on Monday, according to Accern Sentiment Analysis. Accern ranks the sentiment of media coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Seres Therapeutics earned a news sentiment score of 0.18 on Accern's scale. They also gave news stories about the biotechnology company an impact score of 45.33 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near term.
Who are Seres Therapeutics' major shareholders?
Seres Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include NESTLE HEALTH SCIENCE US HOLDINGS, INC. (16.97%), BlackRock Inc. (4.48%), Federated Investors Inc. PA (4.35%), JPMorgan Chase & Co. (1.04%), Millennium Management LLC (0.21%) and Spark Investment Management LLC (0.20%). Company insiders that own Seres Therapeutics stock include David N Cook, Eric D Shaff, John G Aunins, Michele Trucksis and Roger Pomerantz. View Institutional Ownership Trends for Seres Therapeutics.
Which institutional investors are selling Seres Therapeutics stock?
MCRB stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, JPMorgan Chase & Co. and BlackRock Inc.. Company insiders that have sold Seres Therapeutics company stock in the last year include David N Cook, John G Aunins and Roger Pomerantz. View Insider Buying and Selling for Seres Therapeutics.
Which institutional investors are buying Seres Therapeutics stock?
How do I buy shares of Seres Therapeutics?
Shares of MCRB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Seres Therapeutics' stock price today?
One share of MCRB stock can currently be purchased for approximately $8.35.
How big of a company is Seres Therapeutics?
Seres Therapeutics has a market capitalization of $339.45 million and generates $32.10 million in revenue each year. The biotechnology company earns $-89,380,000.00 in net income (profit) each year or ($2.21) on an earnings per share basis. Seres Therapeutics employs 138 workers across the globe.
How can I contact Seres Therapeutics?
Seres Therapeutics' mailing address is 200 SIDNEY STREET, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 617-945-9626.
MarketBeat Community Rating for Seres Therapeutics (MCRB)
MarketBeat's community ratings are surveys of what our community members think about Seres Therapeutics and other stocks. Vote "Outperform" if you believe MCRB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MCRB will underperform the S&P 500 over the long term. You may vote once every thirty days.
Seres Therapeutics (NASDAQ:MCRB) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
8 Wall Street analysts have issued ratings and price targets for Seres Therapeutics in the last 12 months. Their average twelve-month price target is $19.3333, suggesting that the stock has a possible upside of 131.54%. The high price target for MCRB is $20.00 and the low price target for MCRB is $19.00. There are currently 8 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $19.3333 | $18.8571 | $18.75 | $18.75 |
| Price Target Upside: | 131.54% upside | 73.48% upside | 72.49% upside | 72.49% upside |
Seres Therapeutics (NASDAQ:MCRB) Consensus Price Target History
Seres Therapeutics (NASDAQ:MCRB) Analyst Ratings History
Show:
(Data available from 5/28/2016 forward)
Seres Therapeutics (NASDAQ:MCRB) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Seres Therapeutics (NASDAQ MCRB) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 41.90%
Institutional Ownership Percentage: 79.54%
Seres Therapeutics (NASDAQ MCRB) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 5/9/2018 | Roger Pomerantz | Insider | Sell | 233 | $9.00 | $2,097.00 | |  |
| 4/25/2018 | John G Aunins | Insider | Sell | 14,279 | $7.58 | $108,234.82 | 184,485 | |
| 1/26/2018 | David N Cook | Insider | Sell | 1,738 | $11.02 | $19,152.76 | 141,673 | |
| 12/19/2017 | John G Aunins | Insider | Sell | 1,623 | $10.14 | $16,457.22 | 61,060 | |
| 8/29/2016 | John G Aunins | Insider | Sell | 9,390 | $10.87 | $102,069.30 | 192,125 | |
| 7/28/2016 | Michele Trucksis | Insider | Sell | 4,156 | $35.18 | $146,208.08 | 4,156 | |
| 7/27/2016 | Michele Trucksis | Insider | Sell | 38,064 | $35.14 | $1,337,568.96 | 38,064 | |
| 7/25/2016 | John G Aunins | Insider | Sell | 9,390 | $34.18 | $320,950.20 | 220,155 | |
| 7/6/2016 | Roger Pomerantz | CEO | Sell | 88,211 | $29.45 | $2,597,813.95 | 236,468 | |
| 7/1/2016 | Roger Pomerantz | CEO | Sell | 56,789 | $29.81 | $1,692,880.09 | 240,481 | |
| 6/30/2016 | Eric D Shaff | CFO | Sell | 4,533 | $29.54 | $133,904.82 | 4,533 | |
| 6/28/2016 | Eric D Shaff | CFO | Sell | 5,001 | $28.28 | $141,428.28 | 3,334 | |
| 6/27/2016 | John G Aunins | EVP | Sell | 9,390 | $27.23 | $255,689.70 | 32,655 | |
| 6/2/2016 | David N Cook | EVP | Sell | 8,000 | $31.00 | $248,000.00 | 136,673 | |
| 6/2/2016 | Roger Pomerantz | CEO | Sell | 74,049 | $32.52 | $2,408,073.48 | 257,741 | |
| 6/1/2016 | David N Cook | EVP | Sell | 16,000 | $29.43 | $470,880.00 | 144,673 | |
| 6/1/2016 | Roger Pomerantz | CEO | Sell | 70,951 | $30.51 | $2,164,715.01 | 254,643 | |
| 5/25/2016 | Ventures Fund 2007 L Flagship | Major Shareholder | Sell | 1,000,000 | $27.60 | $27,600,000.00 | | |
| 5/24/2016 | Roger Pomerantz | CEO | Sell | 9,801 | $30.00 | $294,030.00 | 193,493 | |
| 5/6/2016 | Roger Pomerantz | CEO | Sell | 8,507 | $24.31 | $206,805.17 | 31,234 | |
| 5/5/2016 | Roger Pomerantz | CEO | Sell | 59,325 | $26.13 | $1,550,162.25 | 51,325 | |
| 5/3/2016 | Roger Pomerantz | CEO | Sell | 67,367 | $28.70 | $1,933,432.90 | 66,414 | |
| 4/25/2016 | John G Aunins | EVP | Sell | 18,640 | $31.94 | $595,361.60 | 56,060 | |
| 4/7/2016 | David N Cook | EVP | Sell | 8,000 | $31.00 | $248,000.00 | 160,673 | |
| 4/7/2016 | Roger Pomerantz | CEO | Sell | 9,212 | $30.00 | $276,360.00 | 24,439 | |
| 4/4/2016 | David N Cook | EVP | Sell | 61,000 | $26.16 | $1,595,760.00 | 183,023 | |
| 4/4/2016 | Eric D Shaff | CFO | Sell | 6,568 | $28.85 | $189,486.80 | 6,568 | |
| 4/4/2016 | Roger Pomerantz | CEO | Sell | 135,788 | $27.20 | $3,693,433.60 | 113,690 | |
| 3/31/2016 | Eric D Shaff | CFO | Sell | 7,663 | $26.30 | $201,536.90 | 7,663 | |
| 3/28/2016 | Eric D Shaff | CFO | Sell | 5,473 | $24.07 | $131,735.11 | 5,473 | |
| 3/28/2016 | John G Aunins | EVP | Sell | 9,390 | $23.89 | $224,327.10 | 74,700 | |
(Data available from 1/1/2013 forward)
Seres Therapeutics (NASDAQ MCRB) News Headlines
| Source: |
|
Seres Therapeutics (NASDAQ:MCRB) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Seres Therapeutics (NASDAQ:MCRB) Income Statement, Balance Sheet and Cash Flow Statement
Seres Therapeutics (NASDAQ MCRB) Stock Chart for Monday, May, 28, 2018
Loading chart…
